Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan 29;12(2):ofaf054.
doi: 10.1093/ofid/ofaf054. eCollection 2025 Feb.

Neurocognitive Impairment Among Cryptococcal Meningitis Survivors in Uganda, a Prospective Cohort Study

Affiliations

Neurocognitive Impairment Among Cryptococcal Meningitis Survivors in Uganda, a Prospective Cohort Study

Laura Nsangi et al. Open Forum Infect Dis. .

Abstract

Background: Neurocognitive impairment in HIV-associated cryptococcal meningitis survivors remains poorly characterized. We sought to identify risk factors associated with sustained neurocognitive impairment.

Methods: Cryptococcal meningitis survivors from the ASTRO-CM trial underwent neurocognitive assessment at 12 weeks. A composite quantitative neurocognitive performance score (QNPZ-8) was calculated as a mean of 8 independent z-scores. Participants were classified by QNPZ-8 score as having mild (QNPZ-8 ≥-1), moderate (-2 < QNPZ-8 < -1), or severe (QNPZ-8 ≤-2) impairment compared with the reference cohort of HIV-negative Ugandan adults. We compared differences in baseline demographics and clinical and laboratory variables by impairment categories.

Results: One hundred fifty-two participants completed ≥5 of the 8 neuropsychological tests and were included in the analysis. Overall, 37% (57/152) exhibited mild (QNPZ-8 ≥-1), 37% (56/152) moderate (-2 < QNPZ-8 < -1), and 26% (39/152) severe impairment (QNPZ-8 ≤-2). The overall mean QNPZ-8 score (SD) of -1.4 (0.82) denoted moderate neurocognitive impairment at 12 weeks. At baseline, lower weight (P = .03), Glasgow Coma Scale score <15 (P = .03), and education ≤7 years (P < .001) were more frequently observed among those with severe neurocognitive impairment at 12 weeks. Education ≤7 years (odds ratio, 6.13; 95% CI, 2.96-12.68; P < .001) and Glasgow Coma Scale score <15 (odds ratio, 2.61; 95% CI, 1.23-5.57; P = .013) were associated with moderate or severe neurocognitive impairment.

Conclusions: Neurocognitive impairment is prevalent at 12 weeks post-treatment in HIV-associated cryptococcal meningitis. Education level and Glasgow Coma Scale score <15 are associated with worse neurocognitive performance. Our findings underscore the need to further evaluate the impact of cryptococcal meningitis on neurocognitive outcomes.

Keywords: HIV; central nervous system infections; cryptococcal meningitis; neurocognitive assessment; neurocognitive impairment.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest. All authors declare no conflicts of interest.

Figures

Figure 1.
Figure 1.
Neurocognitive Z-scores by individual domain score and overall QNPZ-8. Individual domain z-scores are represented as mean and 95% CI. Z-scores have been adjusted so that higher scores reflect better performance. QNPZ-8 score is represented as mean and 95% CI and a boxplot of the median and interquartile range. Abbreviations: AVLT, auditory verbal learning recall; QNPZ-8, composite quantitative neurocognitive performance score.

References

    1. Ellis J, Bangdiwala AS, Cresswell FV, et al. The changing epidemiology of HIV-associated adult meningitis, Uganda 2015–2017. Open Forum Infect Dis 2019; 6:ofz419. - PMC - PubMed
    1. Rajasingham R, Govender NP, Jordan A, et al. The global burden of HIV-associated cryptococcal infection in adults in 2020: a modelling analysis. Lancet Infect Dis 2022; 22:1748–55. - PMC - PubMed
    1. Jarvis JN, Lawrence DS, Meya DB, et al. Single-dose liposomal amphotericin B treatment for cryptococcal meningitis. N Engl J Med 2022; 386:1109–20. - PMC - PubMed
    1. Pasquier E, Kunda J, De Beaudrap P, et al. Long-term mortality and disability in cryptococcal meningitis: a systematic literature review. Clin Infect Dis 2018; 66:1122–32. - PubMed
    1. Kitonsa J, Kiwanuka J, Anywaine Z, et al. Quality of life and associated factors among HIV positive patients after completion of treatment for cryptococcal meningitis. PLoS Negl Trop Dis 2021; 15:e0008983. - PMC - PubMed